D2d Publication: Financial Management of large, multi-center trials

Randomized clinical trials that have public health implications but no or low potential for commercial gain are predominantly funded by governmental (e.g., National Institutes of Health (NIH)) and not-for-profit organizations. Judicious management of research studies’ budgets in a milieu...

Continue reading →

D2d Publication: Baseline characteristics of the D2d cohort

D2d is the largest clinical trial designed specifically to examine the causal relationship between vitamin D supplementation and the development of diabetes. D2d is also the largest U.S.-based study to have assembled and followed a contemporary cohort of people...

Continue reading →

D2d Investigators’ Meeting

The annual meeting of the D2d research team is held in Washington D.C.. On Sunday evening, Principal Investigator Dr. Pittas presents the State of D2d, which remains very strong, especially following the ‘green light’ by the DSMB following its review...

Continue reading →

Interim analysis results are reviewed

The Data and Safety Monitoring Board (DSMB) reviews the results of the interim analysis. This is a critical juncture in the conduct of any clinical trial as the DSMB may recommend that the trial be stopped for futility, safety...

Continue reading →

D2d Publication: Assessment of the NDEP diabetes prevention toolkit

The National Diabetes Education Program created the Small Steps. Big Rewards. GAME PLAN. toolkit to deliver basic type 2 diabetes prevention information to individuals at risk. Among D2d participants who are at risk for diabetes, the GAME PLAN improved knowledge...

Continue reading →

D2d enrolls last participant

A patient from the New York Lenox Hospital site is the 2,423rd and last participant enrolled in D2d. The participant is still in D2d. Congratulations to the amazing research staff at all sites for recruiting a wonderful group of...

Continue reading →

D2d meets enrollment goal

A patient from the Atlanta VA Medical Center site is the 2,382nd participant enrolled in D2d. The study’s recruitment goal is achieved. This is a major accomplishment as most trials never reach their recruitment goal.  The participant is still...

Continue reading →

D2d Publication: Management of hemoglobin variants during hemoglobin A1c testing

When measuring HbA1c, many clinical laboratories do not report the presence of hemoglobin variants, whereas others report them only if they interfere with HbA1c measurement. As routine HbA1c testing may incidentally yield information regarding hemoglobin variants that can affect...

Continue reading →

D2d Investigators’ Meeting

The annual meeting of the D2d research team is held in Arlington, VA. On Sunday evening, principal investigator Dr. Pittas presents the State of D2d, which remains strong and getting stronger. The meeting focuses on participant retention since it...

Continue reading →

D2d enrolls 2,000th participant

A patient from the Pennington Biomedical Research Center site is the 2,000th participant enrolled in D2d. The participant is still in D2d.

Continue reading →